Clinical application of the concept of methotrexate plus 5-FU sequence-dependent "synergy": how good is the evidence?
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004247:DNA / Q000378:metabolism; D004357:Drug Synergism; D005472:Fluorouracil / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D007165:Immunosuppression Therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D010754:Phosphoribosyl Pyrophosphate / Q000378:metabolism; D012313:RNA / Q000378:metabolism; D051381:Rats; D012510:Sarcoma 180 / Q000188:drug therapy; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors
D012313:RNA; D010754:Phosphoribosyl Pyrophosphate; D004247:DNA; D013940:Thymidylate Synthase; D005472:Fluorouracil; D008727:Methotrexate